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Abstract Eales disease (ED) is an idiopathic inflammatory
venous occlusion of the peripheral retina. As neovascula-
rization is prominent in ED, this study attempts to look at
the ratio of VEGF, the angiogenic factor, and PEDF, an
anti-angiogenic factor in the vitreous of ED patients in
comparison with the macular hole (MH) and Proliferative
Diabetic Retinopathy (PDR). Vitreous levels of VEGF and
PEDF were determined in the undiluted vitreous specimen
obtained from 26 ED cases, 17 PDR, and seven patients
with MH. The vitreous levels of VEGF and PEDF were
estimated by ELISA. The immunohistochemistry (IHC) for
VEGF and PEDF were done in the epiretinal membrane of
ED and PDR case. The VEGF/PEDF ratio was found to be
significantly increased in ED (p=0.014) and PDR (p=
0.000) compared to MH. However the ratio was 3.5-fold
higher in PDR than ED (p=0.009). The IHC data on the
ERM specimen from ED showed the presence of VEGF
and PEDF similar to PDR. The high angiogenic potential
seen as the ratio of VEGF/PEDF correlates with the peak
clinical onset of the disease in the age group 21–30 years
and the diseases usually self-resolves above the age of 40,
which is reflected by the low ratio of VEGF/PEDF. The
study shows that the VEGF/PEDF ratio is significantly
increased in ED though the angiogenic potential is higher in
PDR than in ED. Clinically Eales Disease is known as a
self-limiting disease, while PDR is a progressive disease.
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Introduction
Eales disease (ED) is an idiopathic inflammatory venous
occlusion that primarily affects the peripheral retina of
adults. Young adult males have been reported to have an
increased prevalence, with the peak age of onset as 20–
35 years and a reported range of 13–63 years [1, 2].
However, a study of 55 patients by Gieser et al. showed that
men and women were affected equally [3].
ED has been reported from the UK, USA, and Canada
in the later half of nineteenth and early twentieth
centuries. No racial predilection is known in ED.
However, the disease is more prevalent in India and
portions of the Middle East. The reported incidence in
India is one in 200 to 250 ophthalmic patients [1]. The
number of new cases per year in one of the referral
hospital in India where this study was conducted (Sankara
Nethralaya, Chennai, India) for the last 10 years shows an
average of 310 fresh patients per year. Most patients
present with symptoms of floaters, specks, cobwebs,
blurring, or decreased vision associated with vitreous
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toms, but ophthalmic examination reveals early changes of
ED in the other eye. Bilateral involvement is evident in
80–90% of patients. The major manifestations of ED are
inflammation, neovascularization, vitreous hemorrhage,
and retinal detachment. Bilateral involvement is evident
in 80–90% of the patients. There is no known mortality
associated with ED. Stages of ED broadly include stage of
retinal phlebitis, stage of peripheral nonperfusion, and
stageof retinalneovascularization[4]. A new classification
system has been proposed for ED as Stage 1: periphlebitis
of small (1a) and large (1b) caliber vessels with
superficial retinal hemorrhages; Stage 2a: capillary non-
perfusion, Stage 2b: neovascularization elsewhere/of the
disc; Stage 3a: fibrovascular proliferation, Stage 3b:
vitreous hemorrhage; Stage 4a: traction/combined rheg-
matogenous retinal detachment, and Stage 4b: rubeosis
iridis, neovascular glaucoma, complicated cataract, and
optic atrophy [5].
The etiopathogenesis of this disease remains obscure
since its description. Association of ED with several
systemic diseases, mainly tuberculosis, has been reported.
However, in large series, many such associations have not
been proven. Several reports have shown association of a
variety of neurological and hematological disorders with
ED. Immune-mediated mechanism has been proposed by
many authors. However, so far, a precise immunological
mechanism has not been identified [4].
The histopathological hallmark in ED is the adhesion
of leukocytes to the endothelium and the infiltration of
these cells into the retinal parenchyma. Phagocyte-
generated free radicals have been implicated in mediating
tissue damage associated with various inflammatory
vasculopathies. Our earlier studies show elevated levels
of reactive oxygen species and reactive nitrogen species
products correlating with diminished antioxidant status in
patients with ED, and based on these studies, increased
oxidative stress has been strongly implicated in the
etiopathogenesis of ED [2, 6–8].
Intraocularneovascularizationoccursinnumerousischemic
retinal disorders, including diabetic retinopathy, ischemic
retinal-vein occlusion, and retinopathy of prematurity. This
Table 1 Clinical details of the Eales disease cases
S. No. Age/Sex OD/OS Classification Quadrangles Steroid Laser SystemicIllness
1 26/M OD 3b 4 No Not done Nil
2 30/M OS 3b 4 No Sectoral PHC Nil
3 19/M OD 3b 4 Yes Sectoral PHC Nil
4 35/M OD 3b 4 No Sectoral PHC Nil
5 25/M OD 3a 4 No PRP Nil
6 39/M OS 3b 4 No Sectoral PHC Nil
7 33/M OD 3b 4 No Not done Nil
8 29/M OS 3b 4 No Not done Nil
9 36/M OS 4a 4 No Not done HT
10 30/M OD 3b 4 No PRP Nil
11 33/M OD 4a 4 Yes PRP Nil
12 14/M OD 3b 4 Yes PRP Nil
13 51/F OD 3b 4 No PRP Nil
14 36/M OS 3b 4 No PRP Nil
15 24/M OS 3b 4 No PRP Nil
16 28/M OD 4a 4 No Not done Nil
17 45/M OS 3b 4 No Not done Nil
18 35/M OD 3b 4 No Not done Nil
19 34/M OS 3b 4 Yes Not done HT
20 43/M OS 4a 4 No Not done Nil
21 33/M OS 3b 4 No PRP Nil
22 38/M OS 4a 4 No Not done Nil
23 23/M OS 3b 4 No PRP Nil
24 33/M OS 4a 4 No PRP Nil
25 36/M OS 3b 4 No Not done Nil
26 36/M OS 3b 4 No Not done Nil
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detachment,andendothelial-cell-specificangiogenicandvaso-
permeable factor, namely, VEGF, an ischemia-induced ocular
angiogenic factor that has an important role in mediating the
neovascular response of diabetic retinopathy and other
ischemic retinal disorders [9]. Pigment epithelium-derived
growth factor (PEDF) is a glycoprotein and a potent inhibitor
of ischemia induced neovascularization. Decrease in PEDF is
reported in the vitreous of the proliferative diabetic retinopathy
patients [10, 11].
As neovascularization is prominent in ED this study
attempts to look at these two predominant factors one
acting as pro- and the other as anti-angiogenic, by
estimating the VEGF and PEDF levels, respectively, in
the vitreous specimen of ED patients and compare it with
that of the PDR which also involves neovascularization
and with MH which does not involve the same. PDR is
characterized by presence of newly formed blood vessels
arising from the optic disc (NVD) or elsewhere on the
surface of retina (NVE). These new vessels may be flat
along the surface or elevated into the vitreous cavity and
may be with or without a component of glial cell
proliferation, fibrovascular proliferation (FVP). As the
fibrous tissue contracts, the eyes develop recurrent
preretinal and vitreous hemorrhages, tractional retinal
detachment, and is occasionally combined with rhegma-
togenous retinal detachment. A macular hole is a full-
thickness defect of retinal tissue involving the anatomic
fovea, thereby affecting central visual acuity [12]. The
effect of clinical intervention in terms of the steroid and
laser therapy given on the levels of these factors has also
been looked into.
Materials and methods
The study was approved by the Institutional Ethics
committee. Undiluted vitreous samples (0.3–0.5 ml) were
harvested from the midvitreous at the start of vitrectomy.
Vitreous fluid samples were obtained from 26 ED patients
(25M,1F,33±8years),17PDR(11M,6F,54±9years),and
seven patients with macular hole (3 M, 4 F; 60±10 years).
Samples from eyes obtained during repeat vitrectomy were
excluded. All the patients were proved clinically by oph-
thalmologists based on fundus examination by indirect
ophthalmoscopy. As far as the diagnosis of ED is concerned,
initially, the patient presents with retinal perivasculitis
predominantly affecting the peripheral retina (inflammatory
stage), then sclerosis of retinal veins indicating retinal
ischemia (ischemic stage), and finally retinal or optic disk
neovascularization, recurrent vitreous hemorrhage with or
without retinal detachment (proliferative stage).
All patients with idiopathic, full-thickness retinal defect
of more than 400 μm and with posterior vitreous detachment
S. No. Age/sex OD/OS Type of DM Laser Systemic complications Diabetes duration
1 52/M OS 1 PRP HT, CRF 19
2 60/M OD 2 Not done Nil 15
3 58/M OS 2 Not done Nil 11
4 50/M OS 2 PRP CRF 6
5 50/F OS 2 PRP HT, CRF 5
6 59/M OS 2 PRP HT 24
7 42/F OS 1 PRP HT, CRF 15
8 61/M OS 2 PRP HT 15
9 43/F OD 1 PRP HT, CRF, dyslipidemia 3
10 38/M OD 2 Not done Nil 10
11 57/F OS 2 Not done Dyslipidemia 7
12 52/M OS 2 Not done Nil 8
13 67/F OD 2 Not done HT 6
14 42/M OD 1 Not done Nil 10
15 65/M OS 2 PRP HT 7
16 61/M OS 2 PRP HT 16
17 55/F OS 2 Not done HT 10
Table 2 Clinical details of the
proliferative diabetic retinopathy
cases
Table 3 Clinical details of macular hole cases
S. No. Age/sex OD/OS Laser Systemic complications
1 68/M OD Not done IHD
2 41/M OD Not done DM
3 62/F OS Not done HT
4 58/F OD Not done DM
5 69/M OD Not done DM
6 52/F OD Not done Nil
7 62/F OD Not done HT
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the study for the vitreous specimen as the disease control.
Careful slit lamp biomicroscopy is usually sufficient to
establish the diagnosis in the majority of cases. The Watzke–
Allen test is also extremely useful in differentiating FTMHs
from other lesions. Optical coherence tomography is used to
allow detailed cross-sectional examination of macular holes
and may be effective in distinguishing them from other
lesions where doubt exists [13].
All cases of types 1 or 2 diabetes mellitus with ocular
signs namely, NVE, NVD, FVP, vitreous hemorrhage,
tractional retinal detachment, or combined retinal detach-
ment were included in the study for the vitreous specimen
from the PDR cases.
Systemic steroid is given to the ED cases in the form of
prednisolone, 1 mg/kg bodyweight given orally and is
gradually tapered by 10 mg/week. Tables 1, 2, and 3 show
the clinical details of the patients in the study.
Sample collection Vitreous specimens were collected in a
sterile tube, placed immediately on ice, centrifuged at
1,500 rpm for 5 min to separate the cell contents, then
rapidly distributed in two vials, one for VEGF and other for
PEDF immediately frozen at −80°C until processed. During
vitrectomy membrane peeling was done in the eyes with the
ED/PDR, and these were transported in ice to the lab for the
immunohistochemistry (IHC).
Measurement of VEGF and PEDF VEGF levels were
measured in vitreous samples by enzyme-linked immu-
nosorbent assay (ELISA) using the Quantikine VEGF
assay kit (R&D systems) and measurement of PEDF by
using Chemicon International PEDF sandwich ELISA kit
(The ELISA kit and PEDF antibody for immunohisto-
chemistry and Western blot were the generous gift from
Dr. Joyce Tombran-Tink, Penn State College of Medicine,
Hershey).
IHC for VEGF and PEDF in epiretinal membranes The
IHCforVEGFandPEDFwasdonetoconfirmthepresenceof
thesefactorsintheepiretinalmembrane(ERM)ofEDpatients
at the protein level. The epiretinal/fibrovascular membrane
specimen obtained by surgical excision from ED and PDR
cases, respectively, were processed for sectioning after fixing
in buffered formalin. IHC was done on tissue section of 5 μm.
The deparaffinized sections were incubated with trypsin-
EDTA for 30 min and washed with Tris buffered saline
(pH 7.6). Further steps were carried out with Novolink™ min
polymer detection system (kit from Novacastra laboratories
Ltd,NE128EW,UK).Theslideswere blockedfor peroxidase
with hydrogen peroxide provided in the kit for 10 min, and
TBS wash was subsequently given followed by incubation
with protein block for 30 min. After this blocking step, slides
were incubated for 2 h with rabbit polyclonal antibody
directed against VEGF (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and rabbit polyclonal PEDF. A negative
control was done along with, by omitting the primary
antibody. These antibodies were characterized as described
by the suppliers and in the literature and were used at a
dilution of 1:200 for VEGF and 1:150 for PEDF. After
washing with TBS, the slides were incubated for 45 min with
post-primary block (Novolink™ Min polymer detection
system). The slides were washed again and incubated for
45minwithpolymerlink(Novolink™Minpolymerdetection
system). Finally, the slides were washed in TBS and rinsed
with 0.1 M acetate buffer pH 5.0–5.2 and stained for 20 min
with 0.8% Amino ethyl carbazone in acetate buffer (pH 5.0)
(Sigma, St Louis, MO, USA) or DAB as the chromogen
(Novolink™ Min polymer detection system). The sections
were counterstained with Mayer’s haematoxylin for 15 s,
rinsed in tap water and air-dried.
Western blot analysis for PEDF Fifty-microgram proteins
from the vitreous of ED, PDR, and MH were loaded on
10% SDS-PAGE and transblotted to the PVDF membrane.
Particulars Macular hole Eales disease PDR
No. of specimen 7 26 17
Mean age (year) 59±10 (M—3, F—4) 32±8 (M—25, F—1) 54±8 (M—11, F—6)
Mean VEGF (pg/ml) 14.9±9.25 850±1,832 p=0.000 1,001±1,165 p=0.001
Median 13.18 218 327
Table 4 Vitreous levels
of VEGF in MH, ED, and PDR
VEGFisexpressedasmean±SD.
P values are expressed based on
the comparison of the individual
disease with macular hole
Particulars Macular hole Eales disease PDR
No. of specimen 7 26 17
Mean age 59±10 32±8 54±8
Mean PEDF (μg/ml) 7.5±0.7 4.8±3.9, p=0.027 3.74±3.80, p=0.008
Median 7.3 3.9 1.8
Table 5 PEDF levels in the vit-
reous specimen of ED/PDR/MH
PEDFisexpressedasMean±SD.
P values are expressed based
on the comparison of the indi-
vidual disease with macular hole
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50 mM Tris buffer (pH 7.4) followed by incubation for
1 h with a rabbit polyclonal antibody prepared against
human PEDF diluted at 1:3,000 in Tris buffer containing
0.5% milk. After this treatment, the membranes were
washed extensively with Tris buffer and subjected to
further incubation for 30 min in an appropriate dilution of
mouse anti-rabbit IgG–HRP. The HRP color development
was done by chemiluminescence kit (Millipore).
Statistics The results were analyzed using Mann–Whitney
Test and ANOVA. All the statistical analyses were done by
SPSS version 14.0.
Results
Compared to the vitreous of macular hole which showed a
mean VEGF level of 14.9±9.25 pg/ml in the ED, there was
a significant increase to a mean level of 850.5±1832 pg/ml
(p=0.000). Similarly, in PDR cases, the vitreal VEGF level
was significantly increased to 1001.8±1165.8 pg/ml (p=
0.001) compared to disease control namely macular hole.
The median shows that the VEGF levels are similar in both
PDR and ED groups compared to MH (Table 4). But the
levels of PEDF in the vitreous of PDR patients showed a
mean level of 3.74±3.8 μg/ml which is lower than in ED
that had a mean level of 4.8±3.9 μg/ml compared to
macular hole with a mean PEDF level of 7.5±0.7 μg/ml,
(PDR vs. MH: p=0.027 and ED vs. MH: p=0.008). The
median is lower in PDR patients compared to ED cases,
though in both groups, it is lower than MH (Table 5). The
ratio of VEGF to PEDF was found to be significantly
increased in ED (ratio=151±304; p=0.01) and PDR (ratio=
528±742; p=0.000) compared to the macular hole (ratio=
2.01±1.2). However, the ratio was 3.5-fold higher in PDR
than ED, and this ratio is significantly higher in PDR than
in ED (p=0.009; Fig. 1).
The high angiogenic potential is seen as the ratio of
VEGF/PEDF correlates with the peak clinical onset of the
ED in the age group 21–30 years, and the diseases usually
self-resolves above the age of 40, which is reflected by the
low ratio of VEGF/PEDF (Table 6).
The relation between laser treatment and the levels of
VEGF and PEDF in the vitreous of ED patients is shown in
Table 7. The mean VEGF levels were found to be
significantly elevated in the sectoral laser treated group
than the “no laser” group (patients who did not warrant
laser treatment; p=0.026). The PEDF levels and the VEGF/
PEDF ratio too were elevated but were not statistically
significant. Owing to the small sample size, the distribution
profile was made, which shows that the VEGF levels are
distinctly clustered at relatively lower levels in the “no
laser” group compared to both sectoral and PRP. But in the
PDR cases, the “no laser”-treated group (who did not
warrant laser treatment) had VEGF level (mean and the
median) higher than the laser-treated group.
The ED patients under no steroid treatment have lower
VEGF/PEDF ratio in terms of both mean and the median,
though it was not statistically significant. However, the
Fig. 1 VEGF/PEDF ratio in ED (n=26)/MH (n=27)/PDR (n=17).
The p values are given as comparison between MH (disease control)
vs. ED (p=0.01); MH vs. PDR (p=0.000) and PDR vs. ED (p=0.009)
Age group (year) No. of Patients Parameter VEGF pg/ml PEDF μg/ml Ratio
≤20 2 Mean 1,701±567 5.7±8 92.2±130
21–30 8 Mean 2,064±2,975 4.86±3.5 371±475
Median 598 3.9 214
31–40 13 Mean 157±143 4.86±4.1 58.9±111
Median 102 3.5 19.4
>40 3 Mean 50.1±14 3.63±3.1 6.6±6
Median 43 5.4 7.3
P value
21–30 vs. 31–40 years 0.03 NS 0.03
21–30 vs. >40 years 0.28 NS 0.23
Table 6 Relation between age
and VEGF, PEDF levels in the
vitreous of ED patients
24 j ocul biol dis inform (2009) 2:20–28distribution shows that the steroid-treated group has
relatively higher ratio and was maximum in the group
treated with both oral and periocular steroids (Table 8). This
can possibly be explained by the fact that clinically, the
treatment is guided by the severity of disease.
Both VEGF and PEDF were detected in the ERM
specimen from the ED cases as well as in the fibrovascular
membrane from the PDR case (Fig. 2).
The Western blot analysis of the vitreous specimen for
PEDF in ED compared to the PDR and macular hole is
shown in Fig. 3. The densitometry analysis showed that the
band intensity of the PDR is the lowest followed by ED and
macular hole compared to the donor eye vitreous.
Discussion
Ocular neovascularization is regulated by a diffusible
factor, VEGF that promotes angiogenesis in the retina
which is known to play a role in the pathogenesis of early
diabetic retinopathy [14]. In addition, lower levels of
pigment epithelium-derived factor have been related to the
angiogenesis in diabetic retinopathy that results in active
proliferative diabetic retinopathy [15]. It is also well
documented that advanced glycation end products (AGE)–
advanced glycation end product receptor (RAGE) interac-
tion elicited angiogenesis through the transcriptional acti-
vation of the VEGF gene [16]. Interaction of AGEs with
RAGE leads to leukostasis and blood-retinal barrier
breakdown that are characteristic findings in diabetic
retinopathy [17]. While AGEs in the form of methylglyoxal
detected in diabetic membrane and serum suggest the role
of glycation. Results from our previous studies suggest that
AGEs formed through glycoxidation may play an important
role in the development of retinal neovascularization seen
in ED. The immunoreactivity of CML-AGEs (carboxy
methyl lysine) in neovascular membrane and its increased
levels in serum suggest that in spite of the normoglycemic
status, the glycoxidation resulting in AGE and oxidative
stress may trigger the retinal neovascularization in ED.
Therefore, this study was aimed at estimating the VEGF
and PEDF levels in the vitreous specimen of ED and to see
the ratio in comparison with PDR. Present study shows that
the mean VEGF level in the vitreous is significantly
increased in ED compared to MH and the distribution is
similar to that seen in the PDR cases. Ninety-eight percent
of the ED patients and 96% of the PDR cases showed
VEGF levels over and above the median level of the MH
group. The increased levels of VEGF might explain the
severity of the neovascularization and hemorrhage in the
Group No. of patients Parameter VEGF pg/ml PEDF μg/ml Ratio
No Laser 12 Mean 265±297 4.28±3.9 98±132
Median 88 3.6 20
Sectoral Phc 4 Mean 2304±3034 6.85±3.6 444±693
Median 1230 6.25 143
PRP 10 Mean 971±2176 4.56±4.2 98.6±176
Median 217 4.7 33.4
Paired t test
No laser vs. Sectoral Phc p value 0.026 0.265 0.100
No laser vs. PRP p value 0.277 0.873 0.994
Sectoral Phc vs. PRP p value 0.370 0.359 0.148
Table 7 Relation between La-
ser treatment and VEGF, PEDF
levels in the vitreous of ED
patients
Group No. of Patients Parameter VEGF PEDF Ratio
No steroid 9 Mean 222±279 3.98±3.6 71.7±92.7
Median 102 308 12.8
Oral steroids 11 Mean 842±2,073 6.15 125
Median 325 5.5 36.1
Oral + periocular steroids 6 Mean 1,807±2,501 3.48±4.3 320±576
Median 986.5 2.5 108.6
Paired t test
No steroids vs. oral steroids p value 0.38 0.21 0.44
No steroid vs. oral + periocular steroids p value 0.07 0.81 0.21
Oral steroids vs. oral + periocular steroids p value 0.40 0.21 0.31
Table 8 Relation between
steroid intake and the VEGF,
PEDF levels
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shown that high levels of VEGF accumulate in the vitreous
of patients with proliferative diabetic retinopathy, which
results in the mitotic effect on the retinal capillary
endothelial cells [18]. The report by Kumar and Sinha
[19] on intravitreal bevacizumab in ED has been indicative
of role of VEGF in the neovascularization seen in ED.
However, there has been no report on the vitreous levels
of VEGF in the ED cases. The intraocular synthesis of
angiogenic factors is counterbalanced by the synthesis of
antiangiogenic factors. The main antiangiogenic factor is
the PEDF though there are also factors such as transforming
growth factor beta, thrombospondin, and somatostatin [20].
The study revealed that there is a significant decrease in the
PEDF levels in the vitreous of ED cases. Seventy percent of
ED cases show lowered PEDF levels compared to the
median level of MH, and in the PDR group, it is 82%.
PEDF has been proposed as a therapeutic target for
oxidative stress-involved eye diseases, such as PDR [21].
Moreover, it is also earlier reported as an anti-inflammatory
factor that can inhibit VEGF-induced vascular permeability
[22]. In this study, the IHC shows the VEGF and PEDF at
the protein level in the ERM of the ED cases which is
comparable to that of PDR.
The balance between the angiogenic and anti-angiogenic
factors rather than angiogenic factors themselves is said to
be crucial in determining the progression of the angiogenic
vitreoretinopathies such as PDR. Therefore, the ratio of
VEGF/PEDF was analyzed, and the study revealed that the
PDR had the highest ratio followed by ED and the desirable
levels were seen in MH. The ratio was significantly higher
in PDR than in the ED. Higher VEGF/PEDF index values
have been associated with the higher angiogenic potential
[23]. Although VEGF was raised in both diseases, PEDF
was found to be more lowered in the PDR than in ED. But
Fig. 3 Western blot analysis of the vitreous specimen for PEDF in
Eales’ disease compared to the PDR and MH. Panel 1: Western blot
analysis of vitreous PEDF in ED, PDR, MH, and donor eye vitreous.
Panel 2: Beta Actin. Lane 1 donor eye vitreous, Lane 2 MH, Lane 3
ED, Lane 4 ED, Lane 5 PDR, Lane 6 PDR, Lane 7 PDR
Fig. 2 A–C VEGF immunostaining in epiretinal membrane of ED
and PDR is visualized with a red reaction product. A ERM from a
patient with ED negative for secondary antibody; B ERM from ED
patient showing VEGF posivity; C ERM from PDR patient showing
VEGF positivity. D–F PEDF immunostaining in epiretinal membrane
of ED, and PDR is visualized with a red reaction product. D ERM
from ED patient showing PEDF positivity; E ERM from PDR patient
showing PEDF positivity; F ERM from a patient with ED negative for
secondary antibody
ROS/RNS 
Glycoxidation / Lipid peroxidation
AGE 
VEGF/PEDF
Neovascularisation
Fig. 4 Neovascularization
mechanism in Eales’ disease
26 j ocul biol dis inform (2009) 2:20–28thiswas notstatisticallysignificant.However,the ratiogives a
clear picture of the angiogenic potential that was significantly
higher in PDR compared to ED. Clinically, ED is a self-
limiting disease while PDR is a progressive disease.
While looking at the effect of steroid on VEGF, PEDF
levels, and VEGF/PEDF ratio in the ED cases, a subgroup
analysis of the interval between last steroid intake and time
of vitrectomy showed an observation that the VEGF levels
and the VEGF/PEDF ratio were lower in those receiving
steroids between 1 and 6 months preceding surgery as
compared to those receiving steroids in the month imme-
diately preceding surgery. Although multiple factors can
influence the instantaneous levels of VEGF and PEDF in
the vitreous, the treatment with effect to time lag can
explain the above observation. Similarly, the interval
between last laser treatment and time of vitrectomy was
looked into. However, no particular trend was noted here,
and no statistical difference was noted in VEGF, PEDF, and
VEGF/PEDF ratio between the groups (data not shown).
The VEGF levels in the sectoral laser treatment were found
to be significantly higher than the “no laser” group, and the
ratio of VEGF/PEDF was also higher in spite of the increased
PEDF levels. The sectoral laser is done when the disease is
relatively still active while in the PRP the disease is in the
involuntary stage. The PRP group showed the ratio similar to
the “no laser” group. However, the sample sizes have to be
considerably high before drawing any conclusions. Funatsu
et al. have shown a correlation between the VEGF levels
and the grade of photocoagulation [24]. In the PDR patients,
the laser-treated group showed lower angiogenic potential
than the no laser group. Vitreous VEGF levels are reportedly
higher in PDR patients with no laser treatment than the PDR
patients treated with laser. How little the laser treatment is
and the timely treatment can possibly influence the VEGF
and the PEDF levels.
The earlier study from this laboratory has shown the
CML-AGE immunoreactivity detected in all cases of ED
and 61% cases of diabetic retinopathy and none in
idiopathic ERM [25]. AGE accumulation seen also in the
serum of these patients inspite of normoglycemia as against
diabetes was explained based on the glycoxidation process
in ED triggered by the iron-induced oxidative stress [26].
Also, increasing evidence indicates that AGEs promote
retinal alterations through oxidative stress [27, 28]. Though
ageing and hyperglycemia as in ARMD and diabetic
retinopathy, respectively, can result in AGE formation, in
ED, it is very clear that oxidative stress and nitrosative
stress precedes AGE accumulation [6, 29].
The angiogenesis is inhibited normally by inherent
ocular inhibitor—PEDF. Low levels of PEDF along with
increased VEGF has a net angiogenic effect that result in
the neovascularization seen in ED. Oxidative stress may
involve in retinal PEDF downregulation [30]. Further,
PEDF is known to inhibit AGE-induced VEGF expression
[31]. Thus, in ED, increased oxidative stress leads to AGE
formation owing to glycoxidation, which is followed by
AGE–RAGE-mediated VEGF elaborated (Fig. 4). Inflam-
mation, NV, and retinal damage in ED could be explained in
terms of accumulation of lipid and oxygen-free radicals
caused by neovascularization. This is further upregulated by
the low levels of PEDF. Intraocular neovascularization
develops in numerous ischemic retinal vein disorders. In
proliferative diabetic retinopathy, there is active and extensive
proliferation of new vessels that leads to vitreous hemorrhage
and retinal detachment. Though ED is not exactly similar to
diabetic retinopathy wherein the disease is continuous and
ongoing process, in ED, there is an initial insult that may end
up with the proliferative phase. The management depends on
the stage of the disease and consists of (a) treatment with oral
corticosteroids in the active inflammatory stage and (b) laser
photocoagulation in the neovascularization state and vitrecto-
my when there is vitreous hemorrhage or retinal detachment.
The relapse and remission are characteristic of Eales disease
unlike Proliferative diabetic retinopathy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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